C
Royalty Pharma plc
RPRX
$31.17
$0.040.13%
C
Hold
2/11/2025Upgraded
Royalty Pharma plc (RPRX) was upgraded to C from C- on 2/11/2025 due to an increase in the volatility index and total return index.
Royalty Pharma plc (RPRX) was upgraded to C from C- on 2/11/2025 due to an increase in the volatility index and total return index.
C
Hold
2/16/2024Upgraded
Royalty Pharma plc (RPRX) was upgraded to C- from D+ on 2/16/2024 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.16 to $1.1076, net income increased 585.5% from $72.11M to $494.34M, and EBIT increased 304.71% from $151.44M to $612.9M.
Royalty Pharma plc (RPRX) was upgraded to C- from D+ on 2/16/2024 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.16 to $1.1076, net income increased 585.5% from $72.11M to $494.34M, and EBIT increased 304.71% from $151.44M to $612.9M.
D
Sell
8/9/2023Downgrade
Royalty Pharma plc (RPRX) was downgraded to D+ from C- on 8/9/2023 due to a noticeable decline in the growth index, efficiency index and valuation index. EBIT declined 48.05% from $478.97M to $248.84M, operating cash flow declined 41.21% from $1.03B to $607.82M, and earnings per share declined from $0.7641 to $0.5045.
Royalty Pharma plc (RPRX) was downgraded to D+ from C- on 8/9/2023 due to a noticeable decline in the growth index, efficiency index and valuation index. EBIT declined 48.05% from $478.97M to $248.84M, operating cash flow declined 41.21% from $1.03B to $607.82M, and earnings per share declined from $0.7641 to $0.5045.
C
Hold
5/18/2023Upgraded
Royalty Pharma plc (RPRX) was upgraded to C- from D+ on 5/18/2023 due to a noticeable increase in the growth index, valuation index and solvency index. EBIT increased 259.66% from $133.17M to $478.97M, earnings per share increased from -$1.4685 to $0.7641, and operating cash flow increased 81.4% from $569.93M to $1.03B.
Royalty Pharma plc (RPRX) was upgraded to C- from D+ on 5/18/2023 due to a noticeable increase in the growth index, valuation index and solvency index. EBIT increased 259.66% from $133.17M to $478.97M, earnings per share increased from -$1.4685 to $0.7641, and operating cash flow increased 81.4% from $569.93M to $1.03B.
D
Sell
3/7/2023Downgrade
Royalty Pharma plc (RPRX) was downgraded to D+ from C- on 3/7/2023 due to a large decline in the total return index, efficiency index and volatility index. Net income declined 419.72% from $142.65M to -$456.08M, and total capital declined 5.05% from $17.53B to $16.64B.
Royalty Pharma plc (RPRX) was downgraded to D+ from C- on 3/7/2023 due to a large decline in the total return index, efficiency index and volatility index. Net income declined 419.72% from $142.65M to -$456.08M, and total capital declined 5.05% from $17.53B to $16.64B.
C
Hold
12/6/2022Downgrade
Royalty Pharma plc (RPRX) was downgraded to C- from C on 12/6/2022 due to a large decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.6978 to $0.3245, EBIT declined 49.12% from $377.79M to $192.21M, and operating cash flow declined 6.28% from $574.95M to $538.83M.
Royalty Pharma plc (RPRX) was downgraded to C- from C on 12/6/2022 due to a large decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.6978 to $0.3245, EBIT declined 49.12% from $377.79M to $192.21M, and operating cash flow declined 6.28% from $574.95M to $538.83M.
C
Hold
5/6/2022Upgraded
Royalty Pharma plc (RPRX) was upgraded to C from C- on 5/6/2022 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.6673 to $0.1193, EBIT increased 43.22% from $153.42M to $219.72M, and the quick ratio increased from 16.77 to 21.91.
Royalty Pharma plc (RPRX) was upgraded to C from C- on 5/6/2022 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.6673 to $0.1193, EBIT increased 43.22% from $153.42M to $219.72M, and the quick ratio increased from 16.77 to 21.91.
C
Hold
2/17/2022Downgrade
Royalty Pharma plc (RPRX) was downgraded to C- from C on 2/17/2022 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.238 to -$0.6673, EBIT declined 49.38% from $303.05M to $153.42M, and total revenue declined 1.72% from $585.77M to $575.7M.
Royalty Pharma plc (RPRX) was downgraded to C- from C on 2/17/2022 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.238 to -$0.6673, EBIT declined 49.38% from $303.05M to $153.42M, and total revenue declined 1.72% from $585.77M to $575.7M.
C
Hold
1/7/2022Upgraded
Royalty Pharma plc (RPRX) was upgraded to C from C- on 1/7/2022 due to a noticeable increase in the efficiency index, valuation index and solvency index. The quick ratio increased from 9.49 to 10.85, and total capital increased 7.68% from $16.23B to $17.48B.
Royalty Pharma plc (RPRX) was upgraded to C from C- on 1/7/2022 due to a noticeable increase in the efficiency index, valuation index and solvency index. The quick ratio increased from 9.49 to 10.85, and total capital increased 7.68% from $16.23B to $17.48B.
C
Hold
7/23/2021Downgrade
Royalty Pharma plc (RPRX) was downgraded to C- from C on 7/23/2021 due to a decline in the volatility index.
Royalty Pharma plc (RPRX) was downgraded to C- from C on 7/23/2021 due to a decline in the volatility index.
C
Hold
7/6/2021Upgraded
Royalty Pharma plc (RPRX) was upgraded to C from C- on 7/6/2021 due to an increase in the valuation index and dividend index.
Royalty Pharma plc (RPRX) was upgraded to C from C- on 7/6/2021 due to an increase in the valuation index and dividend index.
C
Hold
6/21/2021Downgrade
Royalty Pharma plc (RPRX) was downgraded to C- from C on 6/21/2021 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from $0.4293 to $0.1773, EBIT declined 39.52% from $379.11M to $229.3M, and operating cash flow declined 7% from $565.67M to $526.1M.
Royalty Pharma plc (RPRX) was downgraded to C- from C on 6/21/2021 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from $0.4293 to $0.1773, EBIT declined 39.52% from $379.11M to $229.3M, and operating cash flow declined 7% from $565.67M to $526.1M.
C
Hold
2/25/2021Upgraded
Royalty Pharma plc (RPRX) was upgraded to C from C- on 2/25/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
Royalty Pharma plc (RPRX) was upgraded to C from C- on 2/25/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
C
Hold
12/9/2020Upgraded
Royalty Pharma plc (RPRX) was upgraded to C- from D+ on 12/9/2020 due to an increase in the volatility index and total return index.
Royalty Pharma plc (RPRX) was upgraded to C- from D+ on 12/9/2020 due to an increase in the volatility index and total return index.
D
Sell
11/16/2020Upgraded
Royalty Pharma plc (RPRX) was upgraded to D+ from D on 11/16/2020 due to a substantial increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.09 to $0.7855, EBIT increased 24.73% from $409.35M to $510.57M, and total revenue increased 5.38% from $510.93M to $538.4M.
Royalty Pharma plc (RPRX) was upgraded to D+ from D on 11/16/2020 due to a substantial increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.09 to $0.7855, EBIT increased 24.73% from $409.35M to $510.57M, and total revenue increased 5.38% from $510.93M to $538.4M.
D
Sell
9/9/2020None
Royalty Pharma plc (RPRX) was downgraded to D from U on 09/09/2020.
Royalty Pharma plc (RPRX) was downgraded to D from U on 09/09/2020.
NASDAQ
04/01/2025 4:00PM Eastern
Quotes delayed
